Señales en vivo de PASG | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 16:00):

Stats
Volumen de hoy	41 004.00
Volumen promedio	346 216
Capitalización de mercado	80.71M
EPS	$0 ( 2024-03-04 )
Próxima fecha de ganancias	( $-0.370 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.700
ATR14	$0.0120 (0.92%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Borthwick Kathleen	Buy	227 000	Employee Stock Option (right to buy)
2024-03-15	Forman Mark S	Buy	203 000	Employee Stock Option (right to buy)
2024-03-15	Chou William	Buy	575 000	Employee Stock Option (right to buy)
2024-03-15	Cale Edgar B.	Buy	203 000	Employee Stock Option (right to buy)
2024-02-10	Borthwick Kathleen	Buy	4 000	Common Stock

INSIDER POWER
82.09
Last 96 transactions
Buy: 8 238 559 \| Sell: 441 732

Volumen Correlación

Largo: -0.09 (neutral)

Corto: 0.82 (strong)

Signal:(42.986) Same movement expected

Passage Bio Inc Correlación

10 Correlaciones Más Positivas
REYN	0.916
TARA	0.908
EQ	0.899
KYMR	0.895
FROG	0.894
UNCY	0.893
MRUS	0.89
FWRG	0.887
LECO	0.886
TRIP	0.882

10 Correlaciones Más Negativas
SGLB	-0.894
GRNA	-0.87
KRKR	-0.869
BIOL	-0.865
CAR	-0.864
DCRC	-0.864
SSRM	-0.862
CMLFU	-0.858
RMRM	-0.853
CYAN	-0.851

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Passage Bio Inc Correlación - Moneda/Commodity

-0.11
( neutral )

-0.23
( neutral )

0.00
( neutral )

-0.41
( neutral )

0.33
( neutral )

-0.31
( neutral )

Passage Bio Inc Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-3.72M (0.00 %)
EPS:	$-1.860

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-3.72M (0.00 %)
EPS:	$-1.860

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-3.68M (0.00 %)
EPS:	$-2.51

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-3.48

Financial Reports:

No articles found.

Passage Bio Inc

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Actualizaciones en tiempo real para Passage Bio Inc [PASG]

Upcoming Earnings Alert